Tryptamine Therapeutics launches on ASX with innovative psilocin formulation | News Direct

Tryptamine Therapeutics launches on ASX with innovative psilocin formulation

TRYPTAMINE THERAPEUTICS LIMITED
News release by TRYPTAMINE THERAPEUTICS LIMITED

facebook icon linkedin icon twitter icon pinterest icon email icon Melbourne, Victoria | May 30, 2024 12:00 PM Eastern Daylight Time

Tryptamine Therapeutics Inc. (ASX: TYP) CEO Jason Carroll sits down with Jonathan Jackson in the proactive studio to talk about the start of trading on the Australian Securities Exchange (ASX). Tryptamine, a clinical-stage biotechnology company, is focused on developing an intravenous-infused psilocin formulation for psychedelic-assisted therapy. The company’s core programs include TRP-8803 (IV-infused psilocin formulation) and TRP-8802 (oral psilocybin). TRP-8803 aims to address the limitations of oral psilocybin, offering a faster onset of the psychedelic state, precise control of the experience, and a shorter duration, making it commercially viable. Three open-label trials in the United States using TRP-8802 for fibromyalgia, irritable bowel syndrome (IBS), and binge eating disorder (BED) are underway or recently completed. In a BED study at the University of Florida, TRP-8802 showed over 80% reduction in binge eating episodes and decreased anxiety and depression scores. Tryptamine Therapeutics is supported by a qualified Board, a Scientific Advisory Board, and partnerships with research organisations in the US and Australia. A world-first clinical trial of TRP-8803 will commence in Australia this quarter, with more trials planned for 2024 and 2025.

 

 

Contact Details

 

Proactive Investors

 

Jonathan Jackson

 

+61 413 713 744

 

jonathan@proactiveinvestors.com

project media

Tags

Tryptamine Therapeutics Inc.pharmaceuticalsAsxproactiveAustraliaproactiveInvestors